Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6341172 | 0.70 | SIGMAR1 (0.95) | SIGMAR1HRH3SLC6A2HRH1CHRM2 | |
| Hydrochloric Acid SCHEMBL6338374 | 0.70 | SIGMAR1 (0.97) | SIGMAR1HRH3SLC6A2HRH1CHRM4 | |
| SCHEMBL8123087 | 0.70 | SIGMAR1 (0.71) | SIGMAR1HRH3HRH4 | |
| Hydrochloric Acid SCHEMBL6340307 | 0.69 | SIGMAR1 (0.98) | SIGMAR1HRH3SLC6A2HRH1CHRM4 | |
| Hydrochloric Acid SCHEMBL6338796 | 0.69 | SIGMAR1 (0.98) | SIGMAR1HRH3SLC6A2HRH1CHRM4 | |
| Hydrochloric Acid SCHEMBL6338794 | 0.69 | SIGMAR1 (0.98) | SIGMAR1HRH3SLC6A2HRH1CHRM4 | |
| Hydrochloric Acid SCHEMBL6348916 | 0.69 | SIGMAR1 (0.98) | SIGMAR1HRH3SLC6A2HRH1CHRM4 | |
| Hydrochloric Acid SCHEMBL6347127 | 0.69 | SIGMAR1 (0.98) | SIGMAR1HRH3SLC6A2HRH1CHRM4 | |
| Hydrochloric Acid SCHEMBL6340014 | 0.69 | SIGMAR1 (0.69) | SIGMAR1HRH3HRH4 | |
| SCHEMBL12128786 | 0.69 | HRH3 (0.53) | SIGMAR1HRH3SLC6A2HRH1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1707203-A1 | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands | BIOPROJET (FR) | 2006-10-04 | — | — | EP | claimed |
| EP-1707204-A1 | Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands | BIOPROJET (FR) | 2006-10-04 | — | — | EP | claimed |
| US-8486947-B2 | Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands | BIOPROJET (FR) | 2013-07-16 | — | — | US | disclosed |
| US-8106041-B2 | Combination product comprising an antagonist or inverse agonist of histamine receptor H3 and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs | BIOPROJET (FR) | 2012-01-31 | — | — | US | disclosed |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SCHWARTZ JEAN-CHARLES (FR) | 2011-11-17 | — | — | US | disclosed |
| US-7910605-B2 | Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications | SOCIETE CIVILE BIOPROJET (FR) | 2011-03-22 | — | — | US | disclosed |
| EP-1641461-B1 | COMBINATION PRODUCT COMPRISING AN ANTAGONIST OR INVERSE AGONIST OF HISTAMINE RECEPTOR H<SB>3</SB> AND AN ANTIPSYCHOTIC OR ANTIDEPRESSANT AGENT, AND USE THEREOF FOR THE PREPARATION OF A MEDICAMENT THAT PREVENTS THE ADVERSE EFFECTS OF PSYCHOTROPIC DRUGS | BIOPROJET SOC CIV (FR) | 2010-09-29 | — | — | EP | disclosed |
| US-20090318433-A1 | VERY FAST TIME RESOLVED IMAGING IN MULTIPARAMETER MEASUREMENT SPACE | BIOPROJET (FR) | 2009-12-24 | — | — | US | disclosed |
| US-20090082353-A1 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-03-26 | — | — | US | disclosed |
| EP-2000462-A2 | Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2008-12-10 | — | — | EP | disclosed |
| US-7169928-B2 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | SOCIETE CIVILE BIOPROJECT (FR) | 2007-01-30 | — | — | US | disclosed |
| US-7138413-B1 | Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders | SOCIETE CIVILE BIOPROJET (FR) | 2006-11-21 | — | — | US | disclosed |
| US-20060247223-A1 | Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders | SCHWARTZ JEAN-CHARLES | 2006-11-02 | — | — | US | disclosed |
| EP-1707203-A1 | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands | BIOPROJET (FR) | 2006-10-04 | — | — | EP | disclosed |
| EP-1707204-A1 | Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands | BIOPROJET (FR) | 2006-10-04 | — | — | EP | disclosed |
| US-20060210624-A1 | Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs | BIOPROJET (FR) | 2006-09-21 | — | — | US | disclosed |
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | SCHWARTZ JEAN-CHARLES (FR) | 2004-11-04 | — | — | US | disclosed |
| EP-1100503-B1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ILE BIOPROJET SOC CIV (FR) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318433-A1 | VERY FAST TIME RESOLVED IMAGING IN MULTIPARAMETER MEASUREMENT SPACE | HRH3, HRH4, HCRTR2 | SIGMAR1 23/4885HRH3 1/4885SLC6A2 147/4885 |
| US-20060247223-A1 | Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders | HRH3, HRH4, PNMT | SIGMAR1 64/4885HRH3 1/4885SLC6A2 309/4885 |
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | HTR1A, HRH4, HTR1D | SIGMAR1 67/4885HRH3 6/4885SLC6A2 96/4885 |
| US-20060210624-A1 | Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs | HRH3, HRH4, HRH2 | SIGMAR1 88/4885HRH3 1/4885SLC6A2 215/4885 |
| US-20090082353-A1 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | SIGMAR1 167/4885HRH3 1/4885SLC6A2 522/4885 |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | HRH3, HRH4, HRH2 | SIGMAR1 17/4885HRH3 1/4885SLC6A2 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.